Wednesday, August 10, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

BARDA Backs Antibody Therapy Against MERS Virus

by Global Biodefense Staff
August 22, 2016
MERS CoV Coronavirus

The Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract to Regeneron Pharmaceuticals, Inc. to manufacture and study two antibody therapies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS).

BARDA will provide funding to Regeneron of up to $8.9 million to support packaging and labeling of the antibodies for human use, the preparation and submission of an Investigational New Drug application with the U.S. Food and Drug Administration (FDA), and a National Institutes of Health-conducted clinical trial in healthy volunteers.

“Regeneron has built a unique rapid response platform to address emerging infectious disease threats. In addition to the programs in MERS and Ebola that we are advancing with BARDA, we are also quickly progressing a preclinical program targeting the Zika virus,” said Neil Stahl, Ph.D., Executive Vice President of Research and Development at Regeneron. “We are committed to partnering with the government and other organizations to swiftly address these emerging public health emergencies.”

Regeneron and BARDA have an existing agreement to advance a potential therapy for Ebola that was discovered and developed at Regeneron. The investigational Ebola therapeutic has recently entered a Phase 1 human clinical study and received Orphan Drug Designation from the FDA.

Currently there are no approved medicines or vaccines to treat or prevent MERS, which causes severe respiratory tract infections and is associated with high death rates. Cases of MERS have been reported in the Middle East, South Korea, Europe, the United States, Africa and other countries in Asia.

Tags: AntiviralsASPRAwardsBARDACoronavirusHHSMERS-CoV

Related Posts

Influenza Transmission Spikes During Social Gatherings
Medical Countermeasures

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination
Medical Countermeasures

Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination

July 16, 2022
US Starts Clinical Trial for mRNA Nipah Virus Vaccine
Medical Countermeasures

US Starts Clinical Trial for mRNA Nipah Virus Vaccine

July 11, 2022
Targeting Poxviruses with Messenger RNA Technology
Medical Countermeasures

Targeting Poxviruses with Messenger RNA Technology

July 11, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC